Trump’s administration has eased federal controls on medical marijuana, moving it from a class of highly addictive drugs to a lower‑risk medicine category overseen by the DEA. The shift could slash tax burdens for licensed growers and retailers, which currently face effective rates near 70 percent. The change signals a tentative step toward broader cannabis reform.

If the Treasury makes the relief retroactive, cannabis firms would reclaim up to $2.24 billion in owed taxes, according to Whitney Economics. Public companies like Trulieve and Curaleaf, each owing more than $1.6 billion, could see immediate cash flow improvements. Investors see the tax break as a new entry point for capital inflows.

Reclassification does not legalize cannabis federally; banks, insurers, and payment processors remain wary, keeping costs high. Still, the move removes the drug‑addiction stigma and opens doors for research funding, potentially accelerating FDA approval for treatments in cancer, pain, and seizures. The industry now faces a clearer path to profitability.

Stakeholders worry recreational operators may fall behind as medical rules apply first. Companies like Beak & Skiff fear competitive imbalance while awaiting a broader rescheduling hearing on June 29. Until Congress acts, the split classification could deepen market fragmentation and regulatory uncertainty.